Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

Egypt · Delayed Price · Currency is EGP

5.55

+0.10 (1.83%)

At close: Oct 4, 2026

Market Cap	11.28B +76.1%
Revenue (ttm)	4.39B +22.7%
Net Income	301.01M -24.7%
EPS	0.15 -27.5%
Shares Out	2.03B
PE Ratio	37.25
Forward PE	16.60
Dividend	0.04 (0.72%)
Ex-Dividend Date	Jun 2, 2026

Volume	4,036,126
Open	5.45
Previous Close	5.45
Day's Range	5.44 - 5.62
52-Week Range	3.06 - 7.39
Beta	0.44
Analysts	Buy
Price Target	5.75 (+3.6%)
Est. Earnings	Nov 12, 2026

About EGX:RMDA

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, engages in producing, marketing, selling, and storing pharmaceutical reagents for human and veterinary use. It is also involved in producing, marketing, selling, and storing diagnostic reagents for individuals, laboratories, and hospitals; importing pharmaceutical reagents and raw materials; producing pharmaceutical reagents for human, veterinary, and diagnostic use; and producing food supplements for human use. The company w... [Read more]

Industry Pharmaceutical Preparations

Founded 1986

Country Egypt

Stock Exchange Egyptian Stock Exchange

Ticker Symbol RMDA

Full Company Profile

Financial Performance

In 2025, EGX:RMDA's revenue was 4.10 billion, an increase of 47.94% compared to the previous year's 2.77 billion. Earnings were 268.61 million, a decrease of -26.17%.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for RMDA stock is "Buy." The 12-month stock price target is E£5.75, which is an increase of 3.60% from the latest price.

Price Target

E£5.75

(3.60% upside)

Analyst Consensus: Buy

Stock Forecasts